Pfob, André
Cai, Lie
Schneeweiss, Andreas
Rauch, Geraldine
Thomas, Bettina
Schaefgen, Benedikt
Kuemmel, Sherko
Reimer, Toralf
Hahn, Markus
Thill, Marc
Blohmer, Jens-Uwe
Hackmann, John
Malter, Wolfram
Bekes, Inga
Friedrichs, Kay
Wojcinski, Sebastian
Joos, Sylvie
Paepke, Stefan
Degenhardt, Tom
Rom, Joachim
Rody, Achim
van Mackelenbergh, Marion
Banys-Paluchowski, Maggie
Große, Regina
Reinisch, Mattea
Karsten, Maria Margarete
Sidey-Gibbons, Chris
Wallwiener, Markus
Golatta, Michael
Heil, Joerg
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (German Research Group, GZ:HE 6824/5-1)
Universitätsklinikum Heidelberg
Article History
Received: 9 June 2023
Accepted: 23 October 2023
First Online: 10 November 2023
Ethical Approval
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the respective Ethics Committees at all study sites (lead ethics approval Heidelberg University).
: Informed consent was obtained from all individual participants included in this study.
: Not applicable
: Sherko Kuemmel has received personal fees for consulting or advisory services from Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, PFM Medical, Pfizer, MSD Oncology, Lilly, Sonoscape, Gilead Sciences, Seagen, and Agendia; funding for travel and accommodation expenses from Roche, Daiichi Sankyo, and Sonoscape; and is Co-Director of the WSG Study group. Marc Thill has been a member of the Advisory Boards of Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Biom‘Up, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, PFM Medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Pintuition, and Sysmex; has received manuscript support from Amgen, ClearCut, Clovis, PFM Medical, Roche, and Servier; received funding for travel expenses from Amgen, Art Tempi, AstraZeneca, Clearcut, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, Hexal, I-Med-Institute, Lilly, MCI, Medtronic, MSD, Neodynamics, Norgine, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, and Seagen; received congress support from Amgen, AstraZeneca, Celgene, Daiichi Sanyko, Hexal, Neodynamics, Novartis, Pfizer, Roche, and Sirius Medical; received lecture honoraria from Amgen, Art Tempi, AstraZeneca, Clovis, Connect Medica, Eisai, Exact Sciences, Gedeon Richter, Gilead Science, GSK, Hexal, I-Med-Institute, Jörg Eickeler, Laborarztpraxis Walther et al., Lilly, MCI, Medscape, MSD, Medtronic, Novartis, Onkowissen, Pfizer, PFM Medical, Roche, Seagen, StreamedUp, Sysmex, Vifor, and Viatris; received trial funding from Endomag and Exact Sciences; and received trial honoraria from AstraZeneca, Biom’Up, Celgene, Clearcut, Neodynamics, Novartis, PFM Medical, Roche, and RTI Surgical. Marion van Mackelenbergh has received personal fees, honoraria, or travel grants from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, PierreFabre, Roche, and Seagen. Maggie Banys-Paluchowski has received honoraria for lectures and advisory boards from Roche, Novartis, Pfizer, PFM Medical, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, and ExactSciences; and has received study support from EndoMag, Mammotome, MeritMedical, Gilead, Hologic, and ExactSciences. Mattea Reinisch has received honoraria and/or consultancy fees and/or travel support from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, and Somatex. André Pfob, Lie Cai, Andreas Schneeweiss, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, Toralf Reimer, Markus Hahn, Jens-Uwe Blohmer, John Hackmann, Wolfram Malter, Inga Bekes, Kay Friedrichs, Sebastian Wojcinski, Sylvie Joos, Stefan Paepke, Tom Degenhardt, Joachim Rom, Achim Rody, Regina Große, Maria Margarete Karsten, Chris Sidey-Gibbons, Markus Wallwiener, Michael Golatta, and Joerg Heil have no conflicts of interest to declare in relation to this study.